Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
Sharma A, Al-Khatib SM, Ezekowitz JA, Cooper LB, Fordyce CB, Michael Felker G, Bardy GH, Poole JE, Thomas Bigger J, Buxton AE, Moss AJ, Friedman DJ, Lee KL, Steinman R, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Peterson ED, Inoue LYT, Sanders GD. Sharma A, et al. Among authors: bardy gh. Eur J Heart Fail. 2018 Jun;20(6):1031-1038. doi: 10.1002/ejhf.1192. Epub 2018 May 15. Eur J Heart Fail. 2018. PMID: 29761861 Free article. Clinical Trial.
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Piccini JP, Al-Khatib SM, Hellkamp AS, Anstrom KJ, Poole JE, Mark DB, Lee KL, Bardy GH. Piccini JP, et al. Among authors: bardy gh. Heart Rhythm. 2011 Mar;8(3):393-400. doi: 10.1016/j.hrthm.2010.11.033. Epub 2010 Nov 23. Heart Rhythm. 2011. PMID: 21109025 Free PMC article. Clinical Trial.
Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.
Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. Al-Khatib SM, et al. Among authors: bardy gh. JAMA. 2013 Jan 2;309(1):55-62. doi: 10.1001/jama.2012.157182. JAMA. 2013. PMID: 23280225 Free PMC article.
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials.
Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, Sanders GD. Hess PL, et al. Among authors: bardy gh. Heart Rhythm. 2013 Jun;10(6):828-35. doi: 10.1016/j.hrthm.2013.02.011. Epub 2013 Feb 13. Heart Rhythm. 2013. PMID: 23416381 Free PMC article.
Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Chen J, Johnson G, Hellkamp AS, Anderson J, Mark DB, Lee KL, Bardy GH, Poole JE. Chen J, et al. Among authors: bardy gh. J Am Coll Cardiol. 2013 May 28;61(21):2161-8. doi: 10.1016/j.jacc.2013.02.046. Epub 2013 Mar 26. J Am Coll Cardiol. 2013. PMID: 23541974 Free PMC article. Clinical Trial.
Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?
Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders GD. Al-Khatib SM, et al. Among authors: bardy gh. Int J Cardiol. 2014 Mar 1;172(1):253-4. doi: 10.1016/j.ijcard.2013.12.278. Epub 2014 Jan 10. Int J Cardiol. 2014. PMID: 24467982 No abstract available.
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, Sanders GD. Pun PH, et al. Among authors: bardy gh. Am J Kidney Dis. 2014 Jul;64(1):32-9. doi: 10.1053/j.ajkd.2013.12.009. Epub 2014 Feb 8. Am J Kidney Dis. 2014. PMID: 24518128 Free PMC article.
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Fishbein DP, Hellkamp AS, Mark DB, Walsh MN, Poole JE, Anderson J, Johnson G, Lee KL, Bardy GH; SCD-HeFT Investigators. Fishbein DP, et al. Among authors: bardy gh. J Am Coll Cardiol. 2014 Jun 17;63(23):2560-2568. doi: 10.1016/j.jacc.2014.02.602. Epub 2014 Apr 9. J Am Coll Cardiol. 2014. PMID: 24727258 Free article. Clinical Trial.
183 results